In pursuit of a human chlamydial vaccine

A limited role for antibody in protective immunity induced by rCPAF and CpG vaccination against primary genital Chlamydia muridarum challenge

Mice deficient in B cells (micromT mice) were used to evaluate the role of antibody in enhanced chlamydial clearance and reduction of pathology afforded by vaccination with recombinant chlamydial protease-like activity factor (rCPAF). Enhanced, but comparable, chlamydial clearance was observed in micromT and wild-type (WT) mice after rCPAF+CpG vaccination. Chlamydia-induced pathology was present in mock-immunized animals, but at significantly greater levels in micromT than WT mice, whereas vaccinated micromT and WT mice exhibited similar reductions in pathology. Thus, antibodies may play a role in protection against chlamydial pathology after primary infection, but were largely dispensable in rCPAF+CpG-induced chlamydial clearance and reduction in pathology.

Distinct function of Th1 and Th2 type delayed type hypersensitivity: protective and pathological reactions to chlamydial infection

The role of delayed-type hypersensitivity (DTH) to chlamydial infection has been shown to be a double-edged sword to the host. Reported animal and human studies have, on the one hand, shown that DTH is associated with protective immunity against chlamydial infection and, on the other hand, shown links to immunopathology. Using a murine lung infection model, we recently demonstrated that there might be two different functional types of DTH induced by chlamydial infection based on its association with cytokine patterns. Th1 type DTH is associated with protection while Th2 type DTH is associated with immunopathology. The Th2 type DTH demonstrated in IFNgamma gene knockout (KO) mice is characterized by eosinophil infiltration in addition to mononuclear cell infiltration that exists in Th1 DTH, observed in wild-type C57BL/6 mice and IL-10 KO mice. In addition, the inflammatory cells in IFNgamma KO mice fail to target the cellular sites of chlamydial inclusions in infected tissues and fail to clear the infection. The functional differences in Th1 and Th2 type DTH responses may account for the dual role DTH plays in chlamydial protective immunity and immunopathology.

The potential for vaccine development against chlamydial infection and disease

Chlamydia trachomatis and Chlamydia pneumoniae appear to share a common immunobiology with about 80% of their protein coding genes being orthologs. Progress in DNA vaccine development for C. trachomatis suggests that such a subunit approach may prove useful for C. pneumoniae. The recent finding that it is possible to select for chlamydiae with targeted mutations in key metabolic genes together with the new knowledge of the chlamydia genome also suggests that it may be possible to develop live attenuated strains of chlamydiae for use as vaccine.